The Apothecary Shops to distribute new Pfizer cancer drug
PHOENIX — Specialty pharmacy provider The Apothecary Shops has inked a deal with Pfizer to distribute a new drug for treating kidney cancer.
The specialty provider announced Wednesday that Pfizer had granted it distribution rights for Inlyta (axitinib), which the Food and Drug Administration approved on Jan. 27 for advanced renal cell carcinoma in patients who have failed one systemic therapy.
"The Apothecary Shops is excited to be included in the limited network of pharmacies managing Inlyta," The Apothecary Shops president Keith Cook said. "We have a first-class oncology team, and this announcement certainly reinforces our strong position in the oncology market."
Watson, J&J settle lawsuit over generic contraceptive
PARSIPPANY, N.J. — Subsidiaries of Watson Pharmaceuticals and Johnson & Johnson have settled a lawsuit filed by the latter when Watson attempted to market a generic version of one of its contraceptive drugs.
Watson said Wednesday that Watson Labs and Janssen Pharmaceuticals had settled a patent litigation suit filed in October 2008 over the drug Ortho Tri-Cyclen Lo (norgestimate and ethinyl estradiol). Janssen filed the suit after Watson sought Food and Drug Administration approval for the drug prior to the expiration of a patent covering it; the patent covering the drug’s use in adults is scheduled to expire in June 2019, according to FDA records.
Under the settlement, Janssen will manufacture and supply Watson with an authorized generic version of the drug, while Watson will have the right to market and distribute it and the end of 2015. Other terms of the deal were not disclosed.
FDA approves Sanofi lice treatment
BRIDGEWATER, N.J. — The Food and Drug Administration has approved a head lice treatment made by Sanofi, the drug maker said.
Sanofi announced the approval of Sklice (ivermectin) lotion in the 0.5% strength for patients ages 6 months and older. According to Sanofi, head lice infest an estimated 6 to 12 million children ages 3 to 11 years and costs as much as $1 billion in lost school days and lost work for parents.
"The approval of Sklice lotion provides physicians and parents with a new treatment option for head lice, a condition that is notoriously frustrating to treat," Sanofi-Topaz general manager Kenneth Guito said. "Through a unique mode of action, Sklice lotion resolves most head lice infestations in one application and is very well-tolerated."